Product Images Capecitabine 150mg
View Photos of Packaging, Labels & Appearance
- 72485204 2
- Figure 1 Kaplan-Meier Estimates of Disease-Free Survival (All Randomized Population)a - fig 1
- Figure 2 Kaplan-Meier Estimates of Overall Survival (All Randomized Population) - fig 2
- Figure 3 Kaplan-Meier Curve for Overall Survival of Pooled Data (Studies 1 and 2) - fig 3
- Figure 4 Kaplan-Meier Estimates for Time to Disease Progression Capecitabine and Docetaxel vs Docetaxel - fig 4
- Figure 5 Kaplan-Meier Estimates of Survival Capecitabine and Docetaxel vs Docetaxel - fig 5
- Metabolic Pathway - meta pathway
- Structural Formula - structural formula
Product Label Images
The following 8 images provide visual information about the product associated with Capecitabine 150mg NDC 72485-204 by Armas Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
72485204 2
Capecitabine Tablets, USP is a cytotoxic agent used for cancer treatment. Each tablet contains 150 mg of Capecitabine. It is important to swallow the tablet whole and not crush or cut it. The usual dosage information is available in the package insert. The tablets should be stored in tight containers at a temperature range of 15°C to 30°C. The tablets are manufactured by Shilpa Medicare Ltd. in India and distributed by Armas Pharmaceuticals Inc. in the USA. The product is available in a blister pack containing 60 tablets.*
Figure 1 Kaplan-Meier Estimates of Disease-Free Survival (All Randomized Population)a - fig 1
Figure 2 Kaplan-Meier Estimates of Overall Survival (All Randomized Population) - fig 2
Figure 3 Kaplan-Meier Curve for Overall Survival of Pooled Data (Studies 1 and 2) - fig 3
Figure 4 Kaplan-Meier Estimates for Time to Disease Progression Capecitabine and Docetaxel vs Docetaxel - fig 4
Figure 5 Kaplan-Meier Estimates of Survival Capecitabine and Docetaxel vs Docetaxel - fig 5
This is a table showing estimated probabilities (ranging from 10% to 0%) for different treatment groups. The treatments mentioned are Docetaxel, Capecitabine, and intermittent Widocetaxel for a span of 3 weeks. The dosages mentioned are Docetaxel 100 (mg/sqm/3 weeks), Capecitabine 1250 (mg/sqm twice daily), and intermittent Widocetaxel 75 (mg/sam'3). There is not enough context to determine the purpose of the table or what the probabilities specifically refer to.*
Metabolic Pathway - meta pathway
This is a chemical representation of a reaction involving the drug Capecitabine and two enzymes, Carboxylesterase and Cyd deaminase, which are important in the metabolism of the drug. The structure shows the conversion of Capecitabine to §-DFUR and eventually to 5-FU, which is the active form of the drug used in cancer chemotherapy.*
Structural Formula - structural formula
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
